Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05924321 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Effect of Carbetocin on the QT/QTc Interval in Healthy Subjects
A Phase 1 study of Postpartum Hemorrhage, sponsored by Ferring Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT05924321 is a Phase 1 study of Postpartum Hemorrhage that has completed, run by Ferring Pharmaceuticals. The registered enrollment target is 40 participants, below the 201-participant average among 11 other Postpartum Hemorrhage trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05924321, a Phase 1 study of Postpartum Hemorrhage, has completed, sponsored by Ferring Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
Carbetocin is an oxytocin receptor agonist that selectively binds to receptors in the smooth muscle of the uterus, stimulates rhythmic contractions of the uterus, increases the frequency of existing contractions, and raises the tone of the uterine musculature. Carbetocin is approved in \>100 countries for the prevention of postpartum hemorrhage due to uterine atony in women following cesarean or vaginal delivery. Per regulatory requirements, the current trial will evaluate the effects of high clinical exposure of carbetocin on the QT interval corrected for heart rate (QTc) as measured by ECG in healthy men and women.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Carbetocin
- DRUG Placebo and Moxifloxacin
Study Locations (1)
Arizona
- Ferring Investigational Site - Tempe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2023-05-25 |
| Est. Completion | 2023-09-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05924321
The ClinicalTrials.gov registry entry for NCT05924321 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 201-participant average among 11 other Postpartum Hemorrhage trials with a reported enrollment target (80% lower). The listed sponsor is Ferring Pharmaceuticals, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Postpartum Hemorrhage appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT05924321 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT05924321 about?
NCT05924321 is a clinical study titled "A Study to Evaluate the Effect of Carbetocin on the QT/QTc Interval in Healthy Subjects". Carbetocin is an oxytocin receptor agonist that selectively binds to receptors in the smooth muscle of the uterus, stimulates rhythmic contractions of the uterus, increases the frequency of existing contractions, and raises the tone of the uterine musculature. Carbetocin is approved in \>100 countri...
What is the current status of trial NCT05924321?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2023-05-25. Estimated completion is 2023-09-21.
What conditions does trial NCT05924321 study?
This clinical trial studies the following conditions: Postpartum Hemorrhage.
What interventions are being tested in trial NCT05924321?
The interventions under investigation include: Placebo (DRUG), Carbetocin (DRUG), Placebo and Moxifloxacin (DRUG).
Who is sponsoring clinical trial NCT05924321?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05924321 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Postpartum Hemorrhage
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Effectiveness of the KOKO Device to Treat Primary Abnormal Postpartum Uterine Bleeding or Hemorrhage
RECRUITING · NA
-
Double Simultaneous Uterotonic Agents Versus Single Agent Regimen to Prevent Early Postpartum Hemorrhage
RECRUITING · Phase 3
-
Postpartum Oxytocin Administration in the Era of Delayed Cord Clamping
COMPLETED · NA
-
Calcium Chloride for Prevention of Blood Loss During Intrapartum Cesarean Delivery
COMPLETED · Phase 3
-
Prophylactic Methylergonovine for Twin Cesarean
COMPLETED · Phase 4
-
Prospective Effect of Intravenous Ketorolac on Opioid Use, EBL and Complications Following Cesarean Delivery
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.